<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Longevity Review — February 2026</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Hanken+Grotesk:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Book.ttf') format('truetype'); font-weight: 400; }
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Medium.ttf') format('truetype'); font-weight: 500; }
    *, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }
    :root {
      --text-primary: #111111; --text-secondary: #44403C; --text-tertiary: #78716C;
      --bg-primary: #F9F9F9; --bg-secondary: #FDFDFD; --bg-tertiary: #F7F6F4;
      --bg-hover-darker: #ECEAE7; --line-subtle: #E8E5E1;
      --chart-primary: #2A8F87; --highlight-info: #E3EBF5;
      --serif: 'Copernicus Trial', Georgia, serif; --sans: 'Hanken Grotesk', -apple-system, sans-serif;
      --shadow-card: 0 4px 8px rgba(0,0,0,0.04), 0 2px 4px rgba(0,0,0,0.06);
      --shadow-card-hover: 0 8px 16px rgba(0,0,0,0.06), 0 4px 8px rgba(0,0,0,0.04);
      --radius: 24px;
    }
    html { font-size: 16px; } body { font-family: var(--sans); background: var(--bg-primary); color: var(--text-primary); line-height: 1.65; }
    .nav-bar { display: flex; justify-content: center; background: var(--bg-secondary); font-size: 0.8rem; font-weight: 500; }
    .nav-bar a { text-decoration: none; color: var(--text-tertiary); padding: 0.7rem 1.5rem; margin: 4px 0; border-radius: 999px; transition: all 0.2s; }
    .nav-bar a.active { color: var(--text-primary); background: #ECEAE7; }
    .sector-tabs { display: flex; justify-content: center; gap: 0.5rem; padding: 1rem 1.5rem; background: var(--bg-secondary); flex-wrap: wrap; }
    .sector-tab { font-size: 0.8rem; font-weight: 500; text-decoration: none; padding: 0.5em 1em; border-radius: 999px; color: var(--text-secondary); background: var(--bg-secondary); }
    .sector-tab:hover { background: var(--bg-hover-darker); }
    .sector-tab.active { background: #ECEAE7; color: var(--text-primary); }
    .masthead { background: transparent; position: relative; }
    .masthead-inner { max-width: 900px; margin: 0 auto; padding: 2.5rem 1.5rem 2rem; text-align: center; }
    .masthead .overline { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-bottom: 0.75rem; }
    .masthead h1 { font-family: var(--serif); font-size: clamp(2rem, 5vw, 3rem); font-weight: 400; margin-bottom: 0.5rem; }
    .masthead .edition-date { font-size: 0.95rem; font-weight: 500; color: var(--text-secondary); }
    .masthead .edition-sub { font-size: 0.8rem; color: var(--text-tertiary); }
    .divider-bar { width: 60px; height: 3px; background: var(--text-primary); margin: 1rem auto 0; }
    .lang-toggle { position: absolute; top: 0.75rem; right: 1rem; font-size: 0.65rem; font-weight: 500; }
    .lang-toggle a { text-decoration: none; color: var(--text-tertiary); } .lang-toggle a.active { color: var(--text-primary); }
    .container { max-width: 900px; margin: 0 auto; padding: 2rem 1.5rem 4rem; }
    .section { margin-bottom: 3rem; }
    .section-header { margin-bottom: 1.5rem; }
    .section-title { font-family: var(--serif); font-size: 1.35rem; font-weight: 500; color: var(--text-secondary); }
    .cards { display: grid; gap: 1rem; }
    .card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem 1.5rem; box-shadow: var(--shadow-card); transition: all 0.2s; }
    .card:hover { box-shadow: var(--shadow-card-hover); transform: translateY(-1px); }
    .card-headline { font-family: var(--serif); font-size: 1.25rem; font-weight: 500; margin-bottom: 0.4rem; }
    .card-body { font-size: 1rem; color: var(--text-secondary); line-height: 1.6; }
    .card-tag { display: inline-block; font-size: 0.65rem; font-weight: 600; padding: 0.2em 0.6em; border-radius: 999px; margin-bottom: 0.6rem; background: var(--bg-tertiary); color: var(--text-secondary); }
    .stat-grid { display: grid; grid-template-columns: repeat(4, 1fr); gap: 1rem; margin-bottom: 2rem; }
    .stat-card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem; text-align: center; box-shadow: var(--shadow-card); }
    .stat-value { font-family: var(--serif); font-size: 1.75rem; font-weight: 500; color: var(--chart-primary); }
    .stat-label { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-top: 0.35rem; }
    .highlight-box { background: var(--highlight-info); border-radius: var(--radius); padding: 1.5rem; margin-bottom: 1.5rem; }
    .highlight-title { font-family: var(--serif); font-weight: 500; font-size: 1.1rem; margin-bottom: 0.75rem; }
    .highlight-box p { font-size: 1rem; color: var(--text-secondary); line-height: 1.6; }
    .bottom-line { background: var(--bg-tertiary); border-radius: var(--radius); padding: 2rem; }
    .bottom-line p { font-size: 1rem; line-height: 1.75; color: var(--text-secondary); }
    .footer { text-align: center; padding: 2rem 1.5rem 3rem; font-size: 0.75rem; color: var(--text-tertiary); border-top: 1px solid var(--line-subtle); max-width: 900px; margin: 0 auto; }
    @media (max-width: 640px) {
      .container { width: calc(100vw - 32px); padding: 2rem 0 4rem; margin: 0 auto; }
      .card { background: transparent; box-shadow: none; border-radius: 0; padding: 0 0 1.5rem 0; border-bottom: 1px solid var(--line-subtle); }
      .card:hover { box-shadow: none; transform: none; }
      .stat-grid { grid-template-columns: repeat(2, 1fr); }
    }
  </style>
</head>
<body>
  <nav class="nav-bar">
    <a href="live.html">Live</a><a href="index.html">Daily</a><a href="vc-review.html" class="active">Review</a><a href="archive.html">Archive</a>
  </nav>
  <div class="sector-tabs">
    <a href="vc-review.html" class="sector-tab">VC</a>
    <a href="ai-review.html" class="sector-tab">AI</a>
    <a href="longevity-review.html" class="sector-tab active">Longevity</a>
    <a href="health-wellness-review.html" class="sector-tab">Health</a>
    <a href="space-review.html" class="sector-tab">Space</a>
    <a href="energy-review.html" class="sector-tab">Energy</a>
    <a href="sports-entertainment-review.html" class="sector-tab">Sports</a>
  </div>
  <header class="masthead">
    <div class="lang-toggle"><a href="longevity-review.html" class="active">EN</a><span>/</span><a href="longevity-review-ja.html">JA</a></div>
    <div class="masthead-inner">
      <div class="overline">Daily sector intelligence</div>
      <h1>Longevity review</h1>
      <div class="edition-date">February 17, 2026</div>
      <div class="edition-sub">Anti-aging · Therapeutics · Research · Biotech funding</div>
      <div class="divider-bar"></div>
    </div>
  </header>
  <main class="container">
    <section class="section">
      <div class="section-header"><h2 class="section-title">Market overview</h2></div>
      <div class="stat-grid">
        <div class="stat-card"><div class="stat-value">$48B</div><div class="stat-label">Longevity market 2026</div></div>
        <div class="stat-card"><div class="stat-value">$180M</div><div class="stat-label">Retro Biosciences raise</div></div>
        <div class="stat-card"><div class="stat-value">787%</div><div class="stat-label">KLTO single-day surge</div></div>
        <div class="stat-card"><div class="stat-value">20-40%</div><div class="stat-label">s-KL mouse lifespan gain</div></div>
      </div>
      <div class="highlight-box">
        <div class="highlight-title">The big story</div>
        <p><strong>Klotho protein therapy breaks through.</strong> Klotho Neurosciences (KLTO) announced exclusive licensing of s-KL protein technology that increased mouse lifespan by 20-40% in preclinical studies — the stock surged 787% in a single day. Meanwhile, Retro Biosciences (Bezos-backed) raised $180M and partnered with OpenAI for AI-engineered stem cell proteins. The convergence of AI and longevity research is accelerating timelines dramatically.</p>
      </div>
    </section>
    <section class="section">
      <div class="section-header"><h2 class="section-title">Key developments</h2></div>
      <div class="cards">
        <article class="card">
          <span class="card-tag">Klotho</span>
          <h3 class="card-headline">Klotho Neurosciences secures s-KL protein license — stock surges 787%</h3>
          <p class="card-body">KLTO obtained exclusive license for s-KL (soluble Klotho) protein technology with patents covering USA, Europe, and China. Preclinical data shows <strong>20-40% lifespan extension in mice</strong> via AAV9 vector delivery. Targets age-related neurodegenerative diseases including Alzheimer's and Parkinson's. Won 2025 BioTech Breakthrough Award.</p>
        </article>
        <article class="card">
          <span class="card-tag">AI + Longevity</span>
          <h3 class="card-headline">Retro Biosciences partners with OpenAI for AI-engineered cellular reprogramming</h3>
          <p class="card-body">Bezos-backed Retro raised $180M and partnered with OpenAI to develop <strong>AI-engineered stem cell proteins</strong> targeting cellular reprogramming and autophagy. The collaboration signals deepening AI-longevity convergence — computational approaches now critical for drug discovery timelines.</p>
        </article>
        <article class="card">
          <span class="card-tag">Senolytics</span>
          <h3 class="card-headline">New senolytic compounds reduce epigenetic age in blood samples</h3>
          <p class="card-body">Research published in Molecular Therapy shows JQ1, RG7112, nutlin-3a, and AMG232 <strong>reduced epigenetic age in vitro</strong>. Supports use of these compounds in drug screening for senescence-targeting therapies. First systematic comparison of senolytic efficacy.</p>
        </article>
        <article class="card">
          <span class="card-tag">Reprogramming</span>
          <h3 class="card-headline">Life Biosciences advances partial epigenetic reprogramming to human trials</h3>
          <p class="card-body">Life Biosciences reported positive preclinical data for PER (Partial Epigenetic Reprogramming) platform in optic neuropathies and MASH. <strong>ER-100 advancing to first-in-human trials in 2026</strong> — among the first reprogramming therapies to reach clinical stage.</p>
        </article>
        <article class="card">
          <span class="card-tag">Gene therapy</span>
          <h3 class="card-headline">YouthBio receives FDA support for Alzheimer's gene therapy trial</h3>
          <p class="card-body">FDA supported YouthBio's move to first-in-human trial for <strong>YB002 Alzheimer's gene therapy</strong> following September 2025 INTERACT meeting. Novel approach targets multiple aging pathways simultaneously.</p>
        </article>
        <article class="card">
          <span class="card-tag">AI Drug Discovery</span>
          <h3 class="card-headline">TNIK inhibition identified as potent senomorphic via AI-driven robotics</h3>
          <p class="card-body">Researchers used AI-driven robotic screening to identify <strong>TNIK inhibition as a powerful senomorphic agent</strong>. The compound modulates senescence without killing cells — potentially safer approach than senolytics. Timelines compressed from years to months.</p>
        </article>
        <article class="card">
          <span class="card-tag">Funding</span>
          <h3 class="card-headline">Junevity raises $10M seed for AI-driven siRNA cell reset platform</h3>
          <p class="card-body">Junevity secured $10M seed funding for RESET platform using <strong>siRNA for cell reset</strong> targeting type 2 diabetes, obesity, and longevity applications. AI-driven approach identifies optimal intervention points.</p>
        </article>
        <article class="card">
          <span class="card-tag">Research</span>
          <h3 class="card-headline">DNA Topoisomerase Top2 reduction extends health and lifespan across species</h3>
          <p class="card-body">New research shows reducing Top2 <strong>reprograms the epigenetic landscape</strong> and extends health and lifespan through a conserved mechanism across multiple species. Potential druggable target for aging intervention.</p>
        </article>
      </div>
    </section>
    <section class="section">
      <div class="bottom-line">
        <div class="section-header"><h2 class="section-title">Bottom line</h2></div>
        <p>Longevity is crossing from speculative research to clinical reality. Klotho protein therapy's dramatic preclinical results (20-40% lifespan extension) drove an 787% single-day stock surge — the market is paying attention. The Retro-OpenAI partnership signals that AI acceleration is now essential to longevity research timelines. Multiple approaches (senolytics, reprogramming, gene therapy) are advancing to human trials in 2026. Japan's aging demographics and regulatory leadership make it ground zero for deployment.</p>
        <p style="margin-top: 1rem; font-weight: 600;">Klotho breaks through. AI accelerating timelines. Multiple modalities reaching clinic. Japan leading deployment.</p>
      </div>
    </section>
  </main>
  <footer class="footer"><p>Longevity Review · Compiled by Sanbot · February 17, 2026</p></footer>
</body>
</html>
